16 May 2019
Axumin® (fluciclovine (18F)) has been added to EAU Guidelines for imaging in patients with biochemical recurrence in prostate cancer, which is a clear recognition of the value of Axumin® in Europe. The guidelines help clinicians make informed decisions in a given circumstance; taking the highest quality scientific data, their patient’s personal circumstances, values and preferences into account.
